HCPCS code S0114: Billing guide, coverage and denials

HCPCS code S0114 is a HCPCS Level II temporary code for injectable treprostinil. Its official descriptor reads “Injection, treprostinil, 0.5 mg,” so one billed unit is half a milligram of the drug.

Treprostinil is a prostacyclin analog used to treat pulmonary arterial hypertension, and most prescribers know the injectable form by its brand name, Remodulin. The drug also has a permanent J-code of its own, J3285. That second code drives most of the billing decisions on this page. S0114 is an alternative billing format for a drug that already carries an assigned code.

Most coders meet S0114 when a Medicaid managed care or commercial plan asks for the S-code instead of J3285. The friction starts immediately: Medicare fee-for-service denies S0114 outright, prior authorization rules differ by plan, and the NDC must be attached or the claim bounces.

Key takeaways

HCPCS code S0114 is the temporary S-code for injectable treprostinil, billed in 0.5 mg units

Treprostinil already has a permanent J-code, J3285, which is billed in 1 mg units

The crosswalk carries a conversion: 2 units of S0114 equal 1 unit of J3285

J3490 and J3590 are the wrong codes here, because they are reserved for drugs with no assigned HCPCS code

Inhaled treprostinil is a separate product billed under J7686, so confirm the route before you code

Medicare fee-for-service denies S-codes; Medicaid managed care and commercial plans are the payers that accept S0114

NDC reporting is mandatory for most Medicaid and many commercial payer drug claims billed under S0114

Pabau’s claims management software tracks HCPCS code fields, NDC attachment, and payer-specific rules in one billing workflow

HCPCS code S0114: Official descriptor and code overview

HCPCS code S0114 sits in the HCPCS Level II S-series, a set of temporary codes maintained outside the standard Medicare fee schedule. Its official descriptor is “Injection, treprostinil, 0.5 mg,” which fixes both the drug and the billing unit. S-codes were originally developed by the Blue Cross Blue Shield Association. They capture drugs, supplies, and services that Medicare does not cover but that Medicaid managed care and private payers still need to track. According to CMS’s HCPCS overview, S-codes are not valid for Medicare fee-for-service claims and will be automatically denied.

The quick-reference table below shows the key attributes coders need before submitting any claim under this code.

Coders can verify the current descriptor against the annual CMS Alpha-Numeric HCPCS file or through the AAPC HCPCS code lookup.

What S0114 covers: Inclusions and scope

S0114 covers injectable treprostinil, in 0.5 mg increments, when the claim goes to a payer that accepts S-series codes. That means the subcutaneous and intravenous forms of the drug, which are usually delivered by continuous infusion pump. Inhaled treprostinil is a different product with a different code, so confirm the route before coding the encounter. The inclusion scope depends on four factors.

• Drug identity: the code is specific to treprostinil. A different prostacyclin analog carries its own code, so epoprostenol belongs on J1325 rather than on S0114, however similar the therapy looks in the chart.
• Units of service: one unit of S0114 is 0.5 mg. Convert the documented dose into 0.5 mg units before entering a quantity, and bill what was administered rather than the contents of the vial opened.
• National Drug Code (NDC): the 11-digit NDC identifying the exact product administered must be attached to the claim in the appropriate field. Medicaid requires this on every drug claim; many commercial plans do too.
• Place of service: coverage may be limited to specific settings (office, outpatient hospital, home infusion). Confirm the correct POS code before submitting.

Medical necessity must be documented in the clinical record before the claim is submitted. The chart note must name the pulmonary hypertension diagnosis being treated and confirm the physician order. It must also record the dose and the lot number from the NDC label.

What S0114 does not cover: Exclusions and limitations

Several scenarios fall outside S0114’s coverage even when the drug or supply is otherwise appropriate. Understanding these exclusions prevents avoidable denials.

• Medicare fee-for-service patients: S-codes are not recognized by traditional Medicare. Submitting S0114 to Medicare Part B will result in a CO-4 or CO-97 denial. Bill J3285 instead, with the quantity converted to 1 mg units.
• Medicare Advantage plans: some Medicare Advantage plans do accept S-codes per their individual provider contracts. Verify with the specific plan before assuming non-coverage.
• Payers with no S-code contract: not all commercial payers accept every S-code. If S0114 is not listed in a payer’s formulary or fee schedule, submit the claim under J3285 and halve the unit count.
• Inhaled treprostinil: the inhalation solution is billed under J7686, not under S0114 or J3285. Route of administration decides the code, so an inhaled dose crosswalked to an injection code is a predictable denial.
• Off-label use without documented medical necessity: when the drug is used for a purpose outside the payer’s coverage policy, the claim needs extra documentation. Some plans exclude it entirely.
• Bundled services: the drug may already be included in a global surgical or E&M fee for the same date of service. Separate billing then triggers a CO-97 bundling denial.

Medicare and Medicaid coverage for S0114

Payer acceptance of HCPCS code S0114 varies significantly across program types. The table below maps coverage status by payer category to help coders route claims correctly before submission.

S-code acceptance is contractual rather than statutory, so the payer’s own contract decides it. Verify the patient’s benefits and the plan’s S-code position before each encounter. Run that check ahead of the appointment, not after the drug has been administered.

S0114 prior authorization requirements

Prior authorization (PA) for HCPCS code S0114 is not universal. Whether a plan requires it depends on the payer’s formulary tier, the patient’s diagnosis, and the practice’s provider contract. These steps reflect standard PA workflow for S-code drug claims; confirm the specific payer’s requirements before submission.

1. Confirm PA requirement: call the payer’s provider line or check the online prior authorization portal. Some plans list S0114 on a PA-exempt drug list; others require PA for every injectable supply.
2. Gather clinical documentation: the PA request must include the diagnosis (ICD-10-CM code) and the physician order specifying the drug, dose, and frequency. Add any prior treatment history that shows medical necessity.
3. Submit the PA request: submit electronically through the payer portal where possible. Include the treating provider’s NPI, the practice tax ID, and the place of service.
4. Record the authorization number: once approved, document the PA number in the patient’s record and enter it in Box 23 of the CMS-1500 claim form. Missing PA numbers are a leading denial cause.
5. Appeal a PA denial: if denied, request the clinical criteria used in the decision. Most payers must provide a peer-to-peer review option within 14 days. Submit a written appeal with additional clinical evidence if the peer review is unsuccessful.

How to bill S0114: Step-by-step claim submission

Accurate claim submission for HCPCS code S0114 requires correct field-level data on the CMS-1500. Each field below maps to a common source of denial when completed incorrectly.

Submit the claim electronically where possible. Paper claims for drug codes are processed more slowly and are more prone to transcription errors. An encounter record captured at the point of care populates these fields before the claim reaches the clearinghouse.

Required ICD-10 diagnosis codes to use with S0114

The ICD-10-CM diagnosis code paired with HCPCS code S0114 must reflect the condition driving the infusion. For treprostinil that is pulmonary arterial hypertension, the indication the injectable form is approved to treat. Payers use diagnosis codes to validate medical necessity. A mismatch between the diagnosis and the drug is one of the top denial triggers for S-code claims.

The codes coders reach for sit in the I27 range:

• I27.0 – primary pulmonary hypertension, the WHO Group 1 code most payer policies for treprostinil are written around.
• I27.20 – pulmonary hypertension, unspecified. Treat this as a last resort, since unspecified codes invite medical necessity review.
• I27.21 – secondary pulmonary arterial hypertension, used when another condition is driving the PAH.
• I27.24 – chronic thromboembolic pulmonary hypertension.
• I27.29 – other secondary pulmonary hypertension.

Check the payer’s policy before assuming any of these will pay. Several plans restrict treprostinil coverage to WHO Group 1 disease and deny the Group 3 and Group 4 codes outright.

General rules for ICD-10 pairing with S0114 claims:

• Use the most specific code available. Codes ending in 9, and codes described as unspecified, are a common denial trigger when a better code sits in the record.
• The primary diagnosis in Box 21 must correspond to the condition documented in the physician order for the drug.
• Secondary diagnoses may be listed to provide clinical context but should not contradict the primary.
• Check the payer’s LCD (Local Coverage Determination) or coverage policy to identify diagnosis codes that trigger automatic denial for this drug.

Practices should maintain a reference list of payer-approved diagnosis codes for each drug billed under S-series codes, treprostinil included. That list belongs in the compliance documentation package that supports internal audits.

S0114 vs. related codes: Crosswalk and when to use each

Coders frequently meet HCPCS code S0114 alongside the J-codes for the same drug. The choice between them turns on payer format and route of administration, not on whether a code exists. Treprostinil has a permanent injectable J-code, J3285, whose descriptor reads “Injection, treprostinil, 1 mg.”

S0114 and J3285 describe the same drug at different unit sizes, so the crosswalk carries a conversion. Two units of S0114 equal one unit of J3285, because the S-code counts 0.5 mg per unit and the J-code counts 1 mg.

This is where a common error creeps in. J3490 and J3590 are the unclassified drug and unclassified biologic codes, and they exist only for substances that have no HCPCS code assigned to them. Treprostinil has one, so billing it as an unclassified drug is simply incorrect. It also slows the claim down with an invoice review and often ends in a denial.

Convert the quantity before you rebill. A claim that went out as 40 units of S0114 becomes 20 units of J3285, and leaving the count untouched doubles the billed amount. Units-based edits catch that mismatch quickly, so the corrected claim usually comes back as a denial rather than an overpayment.

Route of administration decides the rest. S0114 and J3285 both describe injectable treprostinil, given subcutaneously or intravenously by infusion pump. The inhaled product is billed under J7686, the non-compounded inhalation solution supplied through durable medical equipment. The diagram below reduces the whole choice to two questions.

Reimbursement rates and fee schedule for S0114

Medicare does not publish an allowed amount for HCPCS code S0114 because the code is not covered by Medicare fee-for-service. Reimbursement is determined entirely by each accepting payer’s contract or fee schedule. Three situations apply depending on which payer is being billed.

• Medicaid fee-for-service: state Medicaid agencies publish drug fee schedules based on Average Manufacturer Price (AMP) or a percentage of Average Wholesale Price (AWP). Check the state’s published fee schedule for the current rate. Rates change quarterly in most states.
• Medicaid managed care organizations: MCO contracts may set rates independently from the state fee schedule. Request the drug fee schedule addendum from the MCO’s provider relations team.
• Commercial managed care: rates are negotiated in the provider contract. Review the contract’s drug fee schedule exhibit or call the payer’s reimbursement line. Many plans use AWP minus a contracted discount percentage.

When a claim crosswalks to J3285, check the quarterly Medicare Part B ASP drug pricing file. It publishes the Medicare payment limit per 1 mg unit. Compare it against an S0114 rate carefully: The J-code unit covers twice as much drug, so a per-unit rate that looks higher may not be. For S0114 specifically, reconcile expected against paid amounts on the remittance advice after each payment posting cycle.

Common claim denial reasons for S0114 and how to fix them

Denial patterns for HCPCS code S0114 cluster around four root causes: Wrong payer, missing NDC, absent prior authorization, and diagnosis mismatch. The table below maps the most common denial codes to their corrective actions.

For a full reference of CARC denial codes paired with next-step actions, see the medical billing denial codes guide. Practices with recurring CO-50 denials on S0114 usually find the fix sits in the documentation rather than in the claim. The chart note must explicitly link the diagnosis to the drug.

Documentation requirements to support S0114 claims

Documentation for HCPCS code S0114 claims must withstand payer audit. A claim that passes automated edits can still be recouped months later if the clinical record does not support the service billed. These are the elements auditors look for.

• Physician order: a dated, signed order specifying the drug, dose, route, and frequency. Verbal orders must be countersigned within the payer’s required timeframe (typically 24-48 hours).
• Clinical chart note: the encounter note for the date of service must document the diagnosis and the clinical rationale for the drug. Record the patient’s response or tolerance too.
• NDC label record: the NDC number printed on the vial or package administered must be recorded in the chart. It has to match the NDC submitted on the claim.
• Dose and unit calculation: the infusion rate, the concentration, and the total dose administered must all be in the record. The arithmetic that turns that dose into 0.5 mg billing units belongs there too. Auditors compare billed units against the dose calculation to flag overbilling.
• Consent documentation: if the drug is used off-label or carries significant risk, a signed informed consent form must be in the record.
• Prior authorization confirmation: the PA approval letter or reference number must be filed with the encounter documentation and match Box 23 on the claim.

Practices that build documentation templates into their intake and encounter workflows catch deficiencies before the claim is submitted rather than after a payer audit. Digital encounter forms that prompt for NDC entry and PA number at the time of service reduce downstream errors significantly.

How Pabau keeps S0114 drug claims clean

A practice billing S0114 usually assembles the claim from three separate places. The payer’s S-code position sits in a spreadsheet, the NDC is copied off the vial by hand, and the prior authorization number arrives by email. Every handoff is a chance for the claim to go out one field short.

Practice management software like Pabau holds those fields on the patient record instead. The HCPCS code, the unit count, the NDC from the vial and the prior authorization number are all captured at the point of service. Pabau’s clean claims management workflow then assembles the claim from that record, not from a retyped summary.

The crosswalk sits in the same place. When a plan turns out not to accept S-codes, the units are already stored in 0.5 mg increments. Moving the line to J3285 is arithmetic rather than a rebuild. Fewer drug claims come back for a field that was in the chart all along.

Struggling with HCPCS claim denials?

Pabau’s claims management tools help practices track HCPCS code fields, attach NDCs, and manage prior authorization numbers in one workflow. Fewer claims come back denied.

Book a demo

Conclusion

The S0114 decision is made before the drug is drawn up, not after the denial arrives. Check whether the plan accepts S-codes, confirm the prior authorization, and record the NDC while the vial is still in hand.

Get that order right and the crosswalk stops being risky. A plan that refuses the S-code gets J3285 with the units halved. The claim then goes out the same week, rather than three weeks later on appeal.

One point is worth holding on to. Treprostinil is a classified drug, so J3490 and J3590 are never the answer, however unfamiliar the payer’s preferred format looks. Book a demo to see how Pabau keeps the code, the units and the NDC together on a drug claim.

Continue your research

Need a framework for managing claim rejections systematically? Denial management in healthcare covers the end-to-end process for tracking, appealing, and reducing recurring payer denials.

Want to understand how the 837 transaction connects to your clearinghouse? 837 electronic claim file explains the EDI format used for electronic claim submission and how errors are flagged before they reach the payer.

Looking for a reference on clean claim standards? Clean claim submission outlines the field-level requirements that prevent automatic rejections on drug and supply claims.

Need the point-of-care record that feeds these claim fields? Superbill documentation sets out what belongs on an encounter record before a drug claim is built from it.

Want to catch a non-accepting payer before the drug is given? Insurance eligibility verification walks through the pre-visit check that decides which code format the claim needs.

Frequently asked questions